Wild-type (senile) amyloidosis electrocardiogram: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 6: Line 6:


==Electrocardiogram==
==Electrocardiogram==
*The EKG findings in wild-type (senile) amyloidosis have low sensitivity and specificity for the condition.<ref>{{Cite journal
| author = [[Ilia G. Halatchev]], [[Jingsheng Zheng]] & [[Jiafu Ou]]
| title = Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies
| journal = [[Journal of thoracic disease]]
| volume = 10
| issue = 3
| pages = 2034–2045
| year = 2018
| month = March
| doi = 10.21037/jtd.2018.03.134
| pmid = 29707360
}}</ref>
*This is because the EKG findings are also common in aging patients in the setting of comorbidities.


* EKG is one of the oldest, best described and most widely used cardiac diagnostic modalities worldwide. However, its use as diagnostic tool for ATTRwt-CA has likely lead to falsely reduced clinical suspicion and its underdiagnoses of the disease.
* This is largely from the “classical” teaching which dictates that cardiac amyloidosis is associated with low voltage
* In recent ATTRwt-CA studies, low voltage has been found to have poor independent sensitivity (~30%) for its diagnosis.
* There are numerous other EKG findings that are seen in patients with ATTRwt-CA but have low sensitivity and specificity for the disease because they are also common in age and comorbidities matched patient cohorts:
** Pseudoinfarct pattern
** Poor R-wave progression
** Atrial fibrillation
** First degree AV block
** Nonspecific ST-T-wave abnormalities
** Left bundle branch block can be potentially useful to differentiate ATTRwt-CA and AL-CA.
* Voltage-to-mass ratio, calculated by sum of S wave in lead V1 plus R wave in lead V5 or V6 (SV1 + RV5 or V6) divided by the echocardiographic muscle cross-sectional area has been shown to have high sensitivity and specificity for ATTRwt-CA.


==References==
==References==

Revision as of 22:13, 17 December 2019

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis electrocardiogram On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis electrocardiogram

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis electrocardiogram

CDC on Wild-type (senile) amyloidosis electrocardiogram

Wild-type (senile) amyloidosis electrocardiogram in the news

Blogs on Wild-type (senile) amyloidosis electrocardiogram

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis electrocardiogram

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Electrocardiogram

  • The EKG findings in wild-type (senile) amyloidosis have low sensitivity and specificity for the condition.[1]
  • This is because the EKG findings are also common in aging patients in the setting of comorbidities.


References

  1. Ilia G. Halatchev, Jingsheng Zheng & Jiafu Ou (2018). "Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies". Journal of thoracic disease. 10 (3): 2034–2045. doi:10.21037/jtd.2018.03.134. PMID 29707360. Unknown parameter |month= ignored (help)